AR065705A1 - Subtipo de amidas selectivas de diazabicicloalcanos - Google Patents
Subtipo de amidas selectivas de diazabicicloalcanosInfo
- Publication number
- AR065705A1 AR065705A1 ARP080101013A ARP080101013A AR065705A1 AR 065705 A1 AR065705 A1 AR 065705A1 AR P080101013 A ARP080101013 A AR P080101013A AR P080101013 A ARP080101013 A AR P080101013A AR 065705 A1 AR065705 A1 AR 065705A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- so2r
- heteroaryl
- effects
- thiadiazol
- Prior art date
Links
- -1 2-oxazolyl Chemical group 0.000 abstract 11
- 230000000694 effects Effects 0.000 abstract 4
- 125000001072 heteroaryl group Chemical group 0.000 abstract 4
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 3
- 125000003118 aryl group Chemical group 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 3
- 125000000623 heterocyclic group Chemical group 0.000 abstract 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
- 125000003342 alkenyl group Chemical group 0.000 abstract 2
- 125000002877 alkyl aryl group Chemical group 0.000 abstract 2
- 125000004429 atom Chemical group 0.000 abstract 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 125000001188 haloalkyl group Chemical group 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 125000001766 1,2,4-oxadiazol-3-yl group Chemical group [H]C1=NC(*)=NO1 0.000 abstract 1
- 125000004505 1,2,4-oxadiazol-5-yl group Chemical group O1N=CN=C1* 0.000 abstract 1
- 125000004515 1,2,4-thiadiazol-3-yl group Chemical group S1N=C(N=C1)* 0.000 abstract 1
- 125000004516 1,2,4-thiadiazol-5-yl group Chemical group S1N=CN=C1* 0.000 abstract 1
- 125000004509 1,3,4-oxadiazol-2-yl group Chemical group O1C(=NN=C1)* 0.000 abstract 1
- 125000004521 1,3,4-thiadiazol-2-yl group Chemical group S1C(=NN=C1)* 0.000 abstract 1
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 abstract 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 abstract 1
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 abstract 1
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 abstract 1
- KDDQRKBRJSGMQE-UHFFFAOYSA-N 4-thiazolyl Chemical group [C]1=CSC=N1 KDDQRKBRJSGMQE-UHFFFAOYSA-N 0.000 abstract 1
- CWDWFSXUQODZGW-UHFFFAOYSA-N 5-thiazolyl Chemical group [C]1=CN=CS1 CWDWFSXUQODZGW-UHFFFAOYSA-N 0.000 abstract 1
- 108010009685 Cholinergic Receptors Proteins 0.000 abstract 1
- KPCZJLGGXRGYIE-UHFFFAOYSA-N [C]1=CC=CN=C1 Chemical group [C]1=CC=CN=C1 KPCZJLGGXRGYIE-UHFFFAOYSA-N 0.000 abstract 1
- 102000034337 acetylcholine receptors Human genes 0.000 abstract 1
- 230000036772 blood pressure Effects 0.000 abstract 1
- 210000004556 brain Anatomy 0.000 abstract 1
- 208000015114 central nervous system disease Diseases 0.000 abstract 1
- 125000004122 cyclic group Chemical group 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 150000002367 halogens Chemical group 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000000324 neuroprotective effect Effects 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 210000002027 skeletal muscle Anatomy 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Los compuestos y composiciones pueden utilizarse para tratar y/o prevenir una gran variedad de enfermedades o trastornos, particularmente trastornos del SNC. Los compuestos se cree que; (i) alteran el numero de receptores colinérgicos nicotínicos del cerebro del paciente, (ii) exhiben efectos neuroprotectores, y (iii) cuando se emplean en cantidades efectivas, no muestran efectos colaterales evidentes, concretamente efectos colaterales en aumentos en presion sanguínea relevantes, efectos negativos en el tracto gastrointestinal, y efectos significantes en el musculo esquelético. Reivindicacion 1: Un compuesto de la formula (1): A-C (O)-Cy (1) o una sal farmacéuticamente aceptable de la misma, caracterizado porque A es un centro diazabicíclico, que contiene átomos de 7, 8 o 9 anillos, y seleccionados del grupo de formulas (2) caracterizado porque el diazabiciclo se une como un radical al carbonilo ilustrado vía uno de los dos átomos de nitrogeno, de manera que el carbonilo forma una union amida con el nitrogeno; Cy es un grupo heteroarilo seleccionado del grupo formado por 2-furanilo, 3-furanilo, 2-tienilo, 3-tienilo, 2-oxazolilo, 4-oxazolilo, 5-oxazolilo, 3-isoxazolilo, 4-isoxazolilo, 5-isoxazolilo, 1,3,4-oxadiazol-2-il, 1,2,4-oxadiazol-3-il, 1,2,4-oxadiazol-5-il, 2-tiazolilo, 4-tiazolilo, 5-tiazolilo, 3-isotiazolilo, 4-isotiazolilo, 5-isotiazolilo, 1,3,4-tiadiazol-2-il, 1,2,4-tiadiazol-3-il, 1,2,4-tiadiazol-5-il, 3-piridinil, y 4-piridinilo, cada uno de los cuales puede sustituirse opcionalmente con hasta tres sustituyentes no hidrogeno seleccionados del grupo formado por alquilo, alquenilo, heterociclilo, cicloalquilo, arilo, heteroarilo, alquilarilo, arilalquilo, halogeno, -OR', -NR'R'', haloalquilo, -CN, -NO2, -CsCR', -SR', -N3 -C(=O)NR'R'', -NR'C(=O)R'', -C(=O)R', -C(=O)OR', -OC(=O)R', -OC(=O)NR'R'', -NR'C(=O)OR'', -SO2R', -SO2NR'R'', y -NR'SO2R''; caracterizado porque cada alquilo, alquenilo, heterociclilo, cicloalquilo, arilo, heteroarilo, alquilarilo, o arilalquilo puede ser sustituido con uno o mas sustituyentes seleccionados del grupo formado por halogeno, -OR', -NR'R'', haloalquilo, -CN, -NO2, -CsCR', -SR', -N3, -C(=O)NR'R'', -NR'C(=O)R'', -C(=O)R', -C(=O)OR', -OC(=O)R', -C(=O)NR'R'', -NR'C(=O)OR'', -SO2R', -SO2NR'R'', y -NR'SO2R'' donde R' y R'' se seleccionan individualmente del grupo formado por hidrogeno, alquilo, cicloalquilo, heterociclilo, arilo, heteroarilo, y arilalquilo, o R' y R'' puede combinarse con los átomos a los cuales se unen para formar una funcionalidad cíclica de 3- a 8- miembros.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US90676207P | 2007-03-13 | 2007-03-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR065705A1 true AR065705A1 (es) | 2009-06-24 |
Family
ID=39580235
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080101013A AR065705A1 (es) | 2007-03-13 | 2008-03-12 | Subtipo de amidas selectivas de diazabicicloalcanos |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20100144700A1 (es) |
| AR (1) | AR065705A1 (es) |
| CL (1) | CL2008000726A1 (es) |
| PE (1) | PE20081893A1 (es) |
| TW (1) | TW200840569A (es) |
| UY (1) | UY30959A1 (es) |
| WO (1) | WO2008112734A1 (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010028033A1 (en) * | 2008-09-05 | 2010-03-11 | Targacept, Inc. | Amides of diazabicyclooctanes and uses thereof |
| BRPI1015043A2 (pt) * | 2009-06-19 | 2019-07-09 | Abbott Lab | derivados de diazahomoadamantano e métodos de uso dos mesmos |
| AU2010328419A1 (en) * | 2009-12-07 | 2012-06-21 | Targacept, Inc. | 3,6-diazabicyclo[3.1.1]heptanes as neuronal nicotinic acetylcholine receptor ligands |
| US9796713B2 (en) * | 2014-06-13 | 2017-10-24 | Bristol-Myers Squibb Company | Tricyclic compounds as alpha-7 nicotinic acetylcholine receptor ligands |
| JP6736661B2 (ja) * | 2015-09-04 | 2020-08-05 | ヤンセン ファーマシューティカ エヌ．ベー． | 治療化合物及び合成 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7135484B2 (en) * | 2002-08-14 | 2006-11-14 | Abbott Laboratories | Azabicyclic compounds are central nervous system active agents |
| US7399765B2 (en) * | 2003-09-19 | 2008-07-15 | Abbott Laboratories | Substituted diazabicycloalkane derivatives |
| PL1697378T3 (pl) * | 2003-12-22 | 2008-04-30 | Memory Pharm Corp | Indole, 1h-indazole, 1,2-benzoizoksazole i 1,2-benzoizotiazole oraz ich wytwarzanie i zastosowania |
| ATE482959T1 (de) * | 2005-08-22 | 2010-10-15 | Targacept Inc | Heteroarylsubstituierte diazatricycloalkane, verfahren zu deren herstellung und deren anwendung |
-
2008
- 2008-02-29 TW TW097107240A patent/TW200840569A/zh unknown
- 2008-03-12 US US12/530,997 patent/US20100144700A1/en not_active Abandoned
- 2008-03-12 AR ARP080101013A patent/AR065705A1/es not_active Application Discontinuation
- 2008-03-12 CL CL200800726A patent/CL2008000726A1/es unknown
- 2008-03-12 UY UY030959A patent/UY30959A1/es not_active Application Discontinuation
- 2008-03-12 PE PE2008000461A patent/PE20081893A1/es not_active Application Discontinuation
- 2008-03-12 WO PCT/US2008/056607 patent/WO2008112734A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| CL2008000726A1 (es) | 2008-06-06 |
| TW200840569A (en) | 2008-10-16 |
| WO2008112734A1 (en) | 2008-09-18 |
| PE20081893A1 (es) | 2009-02-15 |
| UY30959A1 (es) | 2009-09-30 |
| US20100144700A1 (en) | 2010-06-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR063451A1 (es) | Diazabiciclo alcanos como receptores nicotinicos de acetilcolina. composiciones farmaceuticas. | |
| ES2534392T3 (es) | Inhibidores de la proteína tirosina fosfatasa humana y métodos de uso | |
| JP2017537940A5 (es) | ||
| JP2009526761A5 (es) | ||
| AR065705A1 (es) | Subtipo de amidas selectivas de diazabicicloalcanos | |
| JP2013500267A5 (es) | ||
| BRPI0611187A2 (pt) | derivados aminotiazàis como inibidores da estearoil-coa desaturase humana | |
| CR20190320A (es) | N-[4-fluoro-5[[(2s, 4s)-2-metil-4-[(5-metil-1,2,4-oxadiazol-3-il) metoxi]-1-piperidil]metil]tiazol-2-il]acetamida como inhibidor de oga | |
| IL196130A (en) | Compounds that act as inhibitors of the protein beta-human tyrosine phosphatase (hptp-beta), preparations containing them and their use as drugs and in the production of drugs to control blood vessel formation | |
| JP2019520416A5 (es) | ||
| IL185016A (en) | Compounds for the Treatment of Irregular Prosperity | |
| BR112012006686B1 (pt) | compostos de amida substituída, composições farmacêuticas contendo os ditos compostos, e uso dos mesmos para prevenir e/ou tratar doenças causadas pelo lpa | |
| JP2013517286A5 (es) | ||
| JP2008513516A5 (es) | ||
| JP2012519691A5 (es) | ||
| AR056155A1 (es) | Antagonistas del receptor 1 de la hormona de concentracion de melanina no basica | |
| RU2012109554A (ru) | Лиганды сигма-рецепторов для предупреждения или лечения боли, вызванной химиотерапией | |
| RU2017116196A (ru) | 2-амино-6-(дифторметил)-5,5-дифтор-6-фенил-3,4,5,6-тетрагидропиридины как ингибиторы васе1 | |
| JP2019520344A5 (es) | ||
| SI2953948T1 (en) | Fluorinated integrin antagonists | |
| JP2014506582A5 (es) | ||
| JP2013539774A5 (es) | ||
| AR070942A1 (es) | Derivados de azabicicloalcano | |
| JP2016537432A5 (es) | ||
| RU2017105262A (ru) | Способы применения производных циклического амида для лечения опосредуемых сигма-рецепторами расстройств |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |